The paediatric care startup raised the cash in a series B round featuring real estate developer Longfor Properties.
Month: January 2016
SoftBank and Samsung sweeten MyMusicTaste series A
The gig crowdsourcing platform raised $10m in a SoftBank Ventures Korea-led round that will support international growth.
Elastagen stretches to $9m series B
The round, backed by AmorePacific’s corporate venturing unit, will support the clinical advancement of Elastagen’s cosmetic surgery technology.
Qualcomm advertises Heyzap exit after RTNS acquisition
Qualcomm has exited app monetisation company Heyzap in an acquisition by RTNS that could end up being worth up to $45m.
Cortexyme signals corporates for $15m series A
The startup, which is developing treatments for Alzheimer’s disease, received the money in a Pfizer-led round that also included Takeda’s corporate venturing unit.
Monsanto’s CVC unit reveals investment portfolio
Monsanto Growth Ventures, which invests from seed-stage onwards, has backed 11 companies operating in the US, Spain and Estonia.
Alector gets smart with $29.5m series D
Amgen and AbbVie have joined existing backers including Merck and Alphabet for a round led by the corporate and UK government-backed Dementia Discovery Fund.
InSightec focuses itself to raise $22m
The GE and Elbit Imaging-backed company uses focused ultrasound to treat various disorders, and has now raised more than $155m since 1999.
Apple recognises Emotient in acquisition
Intel Capital exited Emotient, which is developing facial recognition technology, after investing in a $6m round in 2013.
Wanda confirms $3.5bn Legendary acquisition
SoftBank is among the exiting investors as conglomerate Dalian Wanda acquires US film and comics producer Legendary Entertainment.
Illumina puts $100m spotlight on Grail
Cancer screening test developer Grail has been spun out of biotech company Illumina with a $100m series A round co-led by Illumina and Arch Venture Partners.
Uber China picks up corporates for new funding
Uber’s China subsidiary raised the undisclosed amount from HNA, Guangzhou Automobile and China Life Insurance at a $7bn pre-money valuation.
Aslan roars to $43m
The oncology drug developer completed a Tianda and Accuron-backed series C round that initially closed at $34m last month, bringing its overall funding to $77m.
Corporates help dig up $48m for Petra
AbbVie, Eli Lilly, Johnson & Johnson, Pfizer, IBM and WuXi PharmaTech are among the backers of a $48m series A round for life sciences startup Petra Pharma.